Diagnóstico e terapêutica dos Transtornos de Ansiedade
Palavras-chave:
subdiagnóstico, medo, ansiedade, farmacologiaResumo
Os transtornos de ansiedade apresentam como características essenciais o medo excessivo e persistente diante de situações que são interpretadas equivocadamente como ameaçadoras, bem como mecanismos de esquiva de ameaças percebidas. Tais transtornos constituem uma das principais causas de incapacidade ao redor do mundo, ocasionando grande sofrimento para os pacientes e seus familiares. Na idade adulta, os transtornos de ansiedade podem ser subdivididos em: fobia específica, transtorno de ansiedade social, transtorno de pânico, agorafobia, transtorno de ansiedade generalizada. O tratamento desses transtornos deve ser feito com uma combinação de psicoterapia e farmacoterapia. Entretanto, a grande maioria dos indivíduos com algum transtorno de ansiedade permanece sem ser tratada pelos profissionais nos sistemas de saúde, em razão das baixas taxas de detecção dessas condições.
Referências
Russell JA. A circumplex model of affect. Journal of personality and social psychology 39, 1161 (1980).
Nardi AE, Fontenelle LF. & Crippa JAS. New trends in anxiety disorders. Brazilian Journal of Psychiatry 34, 5-6 (2012).
Davis M. et al. Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 35, 105 (2010).
APA. Diagnostic and statistical manual of mental disorders: DSM-5TM, 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2013.
Beesdo K, Knappe S. & Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM‑V. Psychiatry Clinical North America 32, 483–524 (2009).
Freeston MH, Rhéaume J, Letarte H, Dugas MJ, Ladouceur R. Why do people worry? Personality and individual differences.17(6):791-802 (1994).
Roy‑Byrne PP. et al. Anxiety disorders and comorbid medical illness. General Hospital Psychiatry 30, 208–225 (2008).
Johansen JP, Hamanaka H, Monfils MH, Behnia R, Deisseroth K, Blair HT, et al. Optical activation of lateral amygdala pyramidal cells instructs associative fear learning. Proceedings of the National Academy of Sciences.107(28):12692-7 (2010).
Ciocchi S, Herry C, Grenier F, Wolff SB, Letzkus JJ, Vlachos I, et al. Encoding of conditioned fear in central amygdala inhibitory circuits. Nature. 468(7321):277 (2010).
Cai H, Haubensak W, Anthony TE, Anderson DJ. Central amygdala PKC-δ+ neurons mediate the influence of multiple anorexigenic signals. Nature neuroscience. 17(9):1240 (2014).
Haubensak W, Kunwar PS, Cai H, Ciocchi S, Wall NR, Ponnusamy R, et al. Genetic dissection of an amygdala microcircuit that gates conditioned fear. Nature. 468(7321):270 (2010).
Li H, Penzo MA, Taniguchi H, Kopec CD, Huang ZJ, Li B. Experience-dependent modification of a central amygdala fear circuit. Nature neuroscience. 16(3):332 (2013).
Penzo MA, Robert V, Li B. Fear conditioning potentiates synaptic transmission onto long-range projection neurons in the lateral subdivision of central amygdala. Journal of Neuroscience. 34(7):2432-7 (2014).
Penzo MA, Robert V, Tucciarone J, De Bundel D, Wang M, Van Aelst L, et al. The paraventricular thalamus controls a central amygdala fear circuit. Nature. 519(7544):455 (2015).
Cullinan WE, Herman JP, Watson SJ. Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis. Journal of Comparative Neurology. 332(1):1-20 (1993).
Dong H-W, Petrovich GD, Swanson LW. Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain research reviews. 38(1-2):192-246 (2001).
Baldwin DS et al. Evidence‑based pharmacological treatment of anxiety disorders, post‑traumatic stress disorder and obsessive‑compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology. 28, 403–439 (2014).
Quagliato LA et al. Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: a meta-analysis of common side effects in acute treatment. Journal of Psychopharmacology, 33(11), 1340-1351 (2019).
